Skip to main content
100924_Rousselot_Hero_CellTherapy.png

Cell therapy and delivery

Local administration of therapeutic cells offers groundbreaking possibilities for treating chronic conditions and ischemic tissues. Rousselot hydrogels offer a promising solution to the challenges associated with targeted therapeutic cell delivery.
Medical grade gelatins

Discover our X-Pure solutions

100424_Rousselot_ContentCard_Embolization_01.png
X-Pure
A range of medical-grade gelatins
100424_Rousselot_ContentCard_Embolization_02.png
X-Pure GelMA
The world’s first GMP grade gelatin methacryloyl
100424_Rousselot_ContentCard_Embolization_03.png
X-Pure GelDAT
The world’s first purified gelatin desaminotyrosine

What is cell therapy?

Cell therapy involves introducing or modifying cells to treat diseases. Recently, authorized treatments like CAR T-cell therapies have made strides in targeting blood cancers. While most cell therapy products are administered intravenously, the local delivery of cells, via injection into or nearby the treatment site, shows potential to treat conditions such as spinal cord injuries, regenerate ischemic tissues, and halt the progression of Parkinson’s disease.

 

The challenges of localized cell delivery

Key challenges for local administration of cells include uniform delivery, maintaining cell viability, and retaining cells at the administration site—critical factors for successful local and regional cell therapies.1

 

Gelatin for cell therapy

Gelatin has a history of safe use in medical applications [link to the blog]. Ultra-purified gelatin such as Rousselot X-Pure, free of pyrogens, will provide a pro-regenerative environment for cells.2 Unlike synthetic hydrogels such as polyethylene glycol3 or natural biomaterials such as alginate4, ultra-purified gelatin is not recognized as foreign by the immune system. Rousselot has developed injectable gels to improve cell viability and retention of cells after local administration. 

STITCH hydrogel platform

Solving cell therapy challenges with STITCH

Rousselot’s STITCH hydrogel platform ensures safety and biocompatibility. It maintains high cell viability and supports cell function. Its shear-thinning properties prevent migration of cells post-delivery. Here’s how it enhances cell therapy:
Verified_Dark_80px_V2
Preventing cell sedimentation
During transport from the production site to the patient, therapeutic cells could sediment in vials or syringes, impacting viability and causing inconsistent dosing. Variability in dosing can lead to safety and performance issues. Hydrogels prevent sedimentation, ensuring uniform dosing and reducing risks.
20240129_Circularity1_Dark_80px_V2.svg
Protecting cells from shear-stress-induced damage during administration
Cells can be damaged by shear stress when injected, compromising their survival and function after transplantation. Even low shear stress can activate damaging molecular cascades. Using a shear-thinning gel reduces this stress, protecting cell viability and function.
20240129_Collagen2_Dark_80px_V2.svg
Retaining cells at the site of injection
A major challenge in local delivery is retaining cells at the injection site. Often, less than 5% of injected cells stay at the target site, as blood vessels, lymphatics, or tissue pressure can displace or remove them, or the cell suspension can flow back through the needle tract. Rousselot has developed hydrogels that prevent cells migration away from the injection site.
20240129_GelatinProcessing_Dark_80px_V2.svg
Improving cell viability post-injection

Even after delivery to the target site, significant cell loss can occur due to cell death or immune system removal. Cells may also experience anoikis, a type of programmed cell death triggered by detachment from the extracellular matrix.

 

Gelatin hydrogels contain RGD sequences (arginine, glycine, and aspartic acid) that mimic the extracellular matrix. Gelatin’s integrin binding sites promote cell adhesion. Additionally, Rousselot’s hydrogels offer temporary protection against macrophages, enhancing cell survival.

Links

Additional information

Webshop (research and technical grades)
*Please note, by accessing the Webshop you will be redirected to a third party website. Rousselot is not liable for its content or the products/services offered on any third party website.

References

  1. Amer, M. H., Rose, F., Shakesheff, K. M., Modo, M., & White, L. J. (2017). Translational considerations in injectable cell-based therapeutics for neurological applications: concepts, progress and challenges. NPJ Regen Med, 2, 23. https://doi.org/10.1038/s41536-017-0028-x
  2. Heinrich MA, Heinrich L, Ankone MJK, Vergauwen B, Prakash J. Endotoxin contamination alters macrophage-cancer cell interaction and therapeutic efficacy in pre-clinical 3D in vitro models. Biomater Adv. 2023 Jan;144:213220. doi: 10.1016/j.bioadv.2022.213220. Epub 2022 Nov 26. PMID: 36476713.
  3. Isaac, A.H., Recalde Phillips, S.Y., Ruben, E. et al. Impact of PEG sensitization on the efficacy of PEG hydrogel-mediated tissue engineering. Nat Commun 15, 3283 (2024). https://doi.org/10.1038/s41467-024-46327-3.
  4. Yang D, Jones KS. Effect of alginate on innate immune activation of macrophages. J Biomed Mater Res A. 2009 Aug;90(2):411-8. doi: 10.1002/jbm.a.32096. PMID: 18523947. https://pubmed.ncbi.nlm.nih.gov/18523947/.
Connect with us

Contact Rousselot